drugset / Trial / NCT03726177

Aspirin for Prevention of Preeclampsia

NCT03726177 ↗

Unknown 600 enrolled Aswan University Hospital
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Prophylaxis with low-dose aspirin has been recommended to prevent preeclampsia, the rationale being that hypertension and abnormalities of coagulation in this disease are caused in part by an imbalance between vasodilating and vasoconstricting prostaglandins. Low-dose aspirin therapy inhibits thromboxane production more than prostacyclin production and therefore should protect against vasoconstriction and pathologic blood coagulation in the placenta. Initially, several single-center trials, mostly among women at increased risk for preeclampsia, demonstrated a substantial reduction in the risk of proteinuric hypertension as well as reductions in the incidences of preterm birth, infants small for gestational age, and perinatal death,

Timeline

Start
2018-12-01
Primary completion
2020-11-30
Completion
2021-01-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aspirin Small molecule 81 mg —
Comparator Aspirin Small molecule 162 mg —

Indications